Skip to main content

Anaphylaxis Checklists

ASCIA has developed the following five checklists to assist in the management of patients who are at risk of severe allergic reactions (anaphylaxis).

Anaphylaxis Checklist - Prescribers (Doctors and Nurse Practitioners) 

Anaphylaxis Checklist - Pharmacists 

Anaphylaxis Checklist - Patients and Carers

 

Anaphylaxis Checklist - Prescribers

pdfASCIA HP Checklist Anaphylaxis Prescribers 2025121.28 KB  

ASCIA HP Checklist Anaphylaxis Prescribers 2025This document has been developed by ASCIA, the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand. ASCIA information is based on published literature and expert review, is not influenced by commercial organisations and is not intended to replace medical advice. For patient or carer support contact Allergy & Anaphylaxis Australia or Allergy New Zealand.

The aim of this checklist is to assist doctors and nurse practitioners who prescribe adrenaline (epinephrine) devices for patients who are at risk of having a severe allergic reaction (anaphylaxis).

There are two brands of adrenaline devices, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are rebated by the PBS in Australia and Pharmac in New Zealand.
  • Anapen® 500 is rebated by the PBS in Australia.

Adrenaline devices are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.
  • Record history of the allergic reaction and suspected triggers using the ASCIA event record form 
  • Prescribe adrenaline device and check that the dose is appropriate (see above). A specialist referral is not required for dose adjustment.
  • Check that the prescription is for two devices, which are rebated by the PBS in Australia and Pharmac in New Zealand.
  • For newly diagnosed patients contact a specialist (allergy, respiratory, paediatrician), if necessary, for authority prescription, pending specialist appointment and inform patient/carer about support organisations, Allergy & Anaphylaxis Australia or Allergy New Zealand 
  • Ensure that the patient has been referred to a clinical immunology/allergy specialist, who is listed on the ASCIA website. allergy.org.au/patients/locate-a-specialist
  • Complete and sign ASCIA Action Plan for Anaphylaxis (RED) - the latest version is on the ASCIA website 
  • Complete ASCIA Travel Plan if required. 
  • Inform patient that they should always carry their adrenaline device/s and ASCIA Action Plan.
  • Ensure the patient/carer understands that that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  • Educate patient/carer on how to give the adrenaline device (using trainer devices), recognition and treatment of allergic reactions, carrying and storage of the adrenaline device and appropriate allergen avoidance measures. For information go to allergy.org.au/anaphylaxis
  • If patient has asthma, review and optimise asthma management and educate about asthma and anaphylaxis. allergy.org.au/patients/asthma-and-allergy/asthma-and-anaphylaxis
  • Inform patient/carer to check and note the expiry date of their device/s.
  • Encourage an appointment every 12 to 18 months, to prescribe new adrenaline device/s before they expire, to review if new allergies have developed or more severe allergic reactions have occurred, and to renew the patient’s ASCIA Action Plan for Anaphylaxis.

For adrenaline device supply updates check www.allergy.org.au/members/adrenaline-device-availability

© ASCIA 2025

Content updated March 2025

For more information go to www.allergy.org.au/hp/anaphylaxis

To support allergy and immunology research go to www.allergyimmunology.org.au/donate 

Anaphylaxis Checklist - Pharmacists

pdfASCIA HP Checklist Anaphylaxis Pharmacists 2025119.6 KB 

This document has been developed by ASCIA, the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand. ASCIA information is based on published literature and expert review, is not influenced by commercial organisations and is not intended to replace medical advice. For patient or carer support contact Allergy & Anaphylaxis Australia or Allergy New Zealand.

ASCIA Anaphylaxis Checklist for PharmacistsThere are two brands of adrenaline (epinephrine) devices, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are rebated by the PBS  in Australia and Pharmac in New Zealand.
  • Anapen® 500 is rebated by the PBS in Australia.

Adrenaline devices are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.
  1. Dispense prescribed adrenaline devices
    • Dispense prescribed devices and check that the dose is appropriate (see above). 
    • Check that the patient has been prescirbed two devices, which are rebated by the PBS in Australia and Pharmac in New Zealand.
    • Remind the customer (patient and/or carer) to check and note the expiry date of their device/s. 
    • Check that the patient has an ASCIA Action Plan for Anaphylaxis (RED) that should have been completed by their doctor or nurse practitioner.
    • Reinforce the need for the patient to always carry their adrenaline device and ASCIA Action Plan.
    • Check that the patient’s asthma is well managed and refer them back to their doctor or nurse practitioner if further action is required. Patients at risk of severe allergic reactions (anaphylaxis) who have asthma that is not well controlled are at increased risk of fatal anaphylaxis.
  2. Dispense non-prescribed adrenaline devices
    • Dispense adrenaline device/s to customers (patients/carers or organisations) for use in addition to prescribed devices or in first aid kits. Non-prescribed devices are not rebated by PBS or Pharmac.
    • Remind the customer to check and note the expiry date of their adrenaline device/s.
    • Check that the customer has an ASCIA First Aid Plan for Anaphylaxis (ORANGE) that should be stored with the non-prescribed device/s. These plans are available at www.allergy.org.au/anaphylaxis
  3. Provide adrenaline device advice, education and training
    • Teach the customer how to use their prescribed or non-prescribed adrenaline device/s using a trainer device. In Australia, trainer devices are available from suppliers or Allergy & Anaphylaxis Australia. In New Zealand, EpiPen trainer devices can be accessed for free at myepipen.co.nz
    • Educate the customer about correct storage of adrenaline devices, away from excessive heat or cooling. 
    • Ensure the customer understands that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  4. Be prepared for an anaphylaxis emergency
    • Train staff to recognise the signs and symptoms of anaphylaxis, how to position the patient, how to administer adrenaline injectors and to phone an ambulance immediately afterwards.
    • Display ASCIA Action First Aid Plans for Anaphylaxis to assist staff in recognising and responding to an anaphylaxis emergency.

For adrenaline device supply updates check www.allergy.org.au/members/adrenaline-device-availability

© ASCIA 2025

Content updated March 2025

For more information go to www.allergy.org.au/hp/anaphylaxis

To support allergy and immunology research go to www.allergyimmunology.org.au/donate

Anaphylaxis Checklist - Patients and Carers

pdfASCIA PC Checklist Anaphylaxis 2025141.03 KB

This document has been developed by ASCIA, the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand. ASCIA information is based on published literature and expert review, is not influenced by commercial organisations and is not intended to replace medical advice. For patient or carer support contact Allergy & Anaphylaxis Australia or Allergy New Zealand.

ASCIA PC Checklist Anaphylaxis 2025There are two brands of adrenaline (epinephrine) devices, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are rebated by the PBS in Australia and Pharmac in New Zealand.
  • Anapen® 500 is rebated by the PBS in Australia.

Adrenaline devices are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.

1. Prescribed adrenaline devices

2. Anaphylaxis and adrenaline device education and training

  • It is important to understand that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  • Complete free ASCIA online anaphylaxis training for community at https://training.ascia.org.au/ to learn how to recognise signs and symptoms of anaphylaxis, how to give an adrenaline device and to know that you need to phone an ambulance immediately afterwards.
  • Ensure that you know how to use an adrenaline device using a trainer device. Trainer devices are available from the supplier or patient/carer support organisations.
  • For further information and support consider joining a patient/carer support organisation (Allergy & Anaphylaxis Australia  or Allergy New Zealand).

3. Other issues to consider

  • Check that your asthma is well managed and see your doctor or nurse practitioner if further action is required. If you are at risk of severe allergic reactions (anaphylaxis) and have asthma that is not well controlled, you are at increased risk of fatal anaphylaxis.
  • Translated ASCIA anaphylaxis information includes the ASCIA First Aid Plan for Anaphylaxis, adrenaline device instructions and general information about anaphylaxis.
  • If you have left an adrenaline device at school, children’s education/care centre or office, ensure that you collect the device before you leave for an extended time (such as school holidays, working or learning from home).

© ASCIA 2025

Content updated March 2025

For more information go to www.allergy.org.au/patients/about-allergy

To support allergy and immunology research go to www.allergyimmunology.org.au/donate

Adrenaline Device PBS Authority Form

This form can be used to request an authority from a clinical immunology/allergy specialist for an initial PBS Authority prescription of EpiPen® or EpiPen Jr® or Anapen® 500 adrenaline (epinephrine) injector devices. The form has been updated in July 2024 to include Anapen® 500, and to make it easier to find on the ASCIA website. 

When completing the form please refer to ASCIA Guidelines - Adrenaline (Epinephrine) Injector Prescription - www.allergy.org.au/hp/anaphylaxis/adrenaline-injector-prescription 

pdfASCIA PBS adrenaline device authority112.5 KB

docxASCIA PBS adrenaline device authority26.32 KB

ASCIA adrenalie device authority request

Content updated August 2024

Translations of anaphylaxis information

Translations of anaphylaxis information

Quick links to translated ASCIA anaphylaxis information. 

  • First Aid for Anaphylaxis - English
    First Aid for Anaphylaxis | English

  • First Aid for Anaphylaxis - Other Languages
    First Aid for Anaphylaxis | Other Languages

  • First Aid for Anaphylaxis - Maori, Samoan, Tongan
    First Aid for Anaphylaxis | NZ - Maori, Samoan, Tongan

  • Anaphylaxis Patient Information - English
    Anaphylaxis Patient Information | English

  • Anaphylaxis Patient Information - Other Languages
    Anaphylaxis Patient Information | Other Languages

  • Anaphylaxis Patient Information - Maori, Samoan, Tongan
    Anaphylaxis Patient Information | NZ - Maori, Samoan, Tongan

  • Anaphylaxis Fact Sheet for Parents - English
    Anaphylaxis Fact Sheet for Parents | English

  • Anaphylaxis Fact Sheet for Parents - Other Languages
    Anaphylaxis Fact Sheet for Parents | Other Languages

  • Anaphylaxis Fact Sheet for Parents - Maori, Samoan, Tongan
    Anaphylaxis Fact Sheet for Parents | NZ - Maori, Samoan, Tongan

  • How to give an adrenalin injector - English
    How to give an adrenaline injector | English

  • How to give EpiPen - Other Languages
    How to give EpiPen | Other Languages

  • How to give EpiPen - Maori, Samoan, Tongan
    How to give EpiPen | NZ - Maori, Samoan, Tongan


Other ASCIA information for patients and carers can be translated using ReadSpeaker, by highlighting the text, clicking on 'translate’ and selecting the language.

Translations of chef cards are available from the Allergy & Anaphylaxis Australia website
https://allergyfacts.org.au/resources/aaa-translated-chef-card-template

Translations of asthma action plans are available from the National Asthma Council website 
www.nationalasthma.org.au/health-professionals/asthma-action-plans/translated-action-plans

General allergy and anaphylaxis information

Other health professional information is available here: www.allergy.org.au/hp/papers

Information for patients and carers is available here: www.allergy.org.au/patients/information 

Patient and carer support organisations are listed here: www.allergy.org.au/patients/patient-support-organisations

Content created October 2022

Read more …Translations of anaphylaxis information